T1	Participants 712 800	873 patients were randomly assigned to receive sunitinib (n = 584) or placebo (n = 289).
T2	Participants 346 489	Men with progressive mCRPC after docetaxel-based chemotherapy were randomly assigned 2:1 to receive sunitinib 37.5 mg/d continuously or placebo
